中
  • HOME

  • Company

    • GenFleet Overview
    • Vision & Mission
    • Management Team
    • Advisory Board
    • Company History
    • CSR Philosophy
  • Science

    • Our Pipeline
    • Selected Targets
    • R&D Platform
  • Media

    • Press Release
    • Media Coverage
  • Investors

    • Institutional Investors
    • IR Announcements
  • Careers

    • Overview
    • Culture
    • Highlights
    • Benefits
    • Join Us
  • Contact

jinfangLOGOzuhejihekouhao-05.png

HOME

Company

  • GenFleet Overview
  • Vision & Mission
  • Management Team
  • Advisory Board
  • Company History
  • CSR Philosophy

Science

  • Our Pipeline
  • Selected Targets
  • R&D Platform

Media

  • Press Release
  • Media Coverage

Investors

  • Institutional Investors
  • IR Announcements

Careers

  • Overview
  • Culture
  • Highlights
  • Benefits
  • Join Us

Contact

中
Home
Media
Press Release
  • 2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients

    The data demonstrated promising anti-tumor activity and tolerability among patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). This trial (NCT04914286) is the first global multi-center study of a TGF-β R1 inhibitor combined with an anti-PD-1 antibody conducted by a Chinese biotech.

    Jun 06, 2023
  • China's First NDA for a KRAS G12C Inhibitor: GenFleet Annoucnes NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation

    It’s the first China-developed KRAS G12C inhibitor that has its NDA submission accepted and granted with Priority Review Designation by NMPA. GFH925 also received Breakthrough Therapy Designations this year for treating advanced KRAS G12C-mutant NSCLC that have received at least one systemic therapy and colorectal carcinoma (CRC) patients who have received at least two systemic therapies.

    Nov 24, 2023
  • GFH009 Granted with FDA Fast Track Designation for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas

    The phase I, multi-center trial of GFH009 monotherapy for r/r hematological malignancies has completed its dose escalation portion in both China and the US. Clinical trials of GFH009 demonstrated significant reduction in expression of proto-oncogenes such as MYC, MCL1 among patients with hematological malignancies including PTCL. Four PTCL patients(36.4%)were observed with clinical response including one in a continuous treatment for over 56 weeks. GenFleet has started its phase Ib/II trial of G

    Oct 31, 2023
  • GenFleet Announces GFH009 Granted with FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia

    Preliminary results from GFH009 monotherapy study for relapsed/refractory hematological malignancies demonstrated favorable safety/tolerability of GFH009 with no unexpected dose limiting toxicities or hematological toxicities difficult to determine in patients. With regard to efficacy, the study exhibited GFH009’s anti-tumor activity of up to 77.3% bone marrow blast reduction and desired levels of MCL1 & MYC suppression in peripheral blood with decrease in MCL1 or MYC observed in 97% (66/68)

    Oct 12, 2023
  • GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

    The phase I, multi-center trial of GFH009 monotherapy for relapsed/refractory hematological malignancies has completed its dose escalation portion in both China and the US. Preliminary results demonstrated favorable safety/tolerability and promising clinical efficacy of GFH009. Complete or partial responses were observed in acute myeloid leukemia and lymphoma patients; four PTCL patients (36.4%) were observed with clinical response including one in a continuous treatment for over 48 weeks. The r

    Oct 10, 2023
  • GenFleet Therapeutics Enters Discovery and Development Collaboration with Verastem to Advance Three Oncology Programs in Areas of High Unmet Need

    The terms of the agreement include combined upfront, research support and option payments to GenFleet of $11.5 million for the first program, with potential total deal size across all programs up to $625.5 million excluding royalties.

    Aug 28, 2023
  • First Patient Dosed in Phase IIa Combination Study of GFH009 with Venetoclax and Azacitidine Treating Acute Myeloid Leukemia Patients

    The Phase 2a clinical trial is an open label, single arm, multi-center study that is designed to evaluate safety, tolerability, and efficacy at two dose levels of GFH009 (once weekly 45 mg or 60 mg) in combination with aza/ven. The study will enroll up to 20 r/r AML patients, 10 patients per dose level, all of whom will receive standard doses of aza/ven after they became unresponsive to venetoclax combinations including aza/ven, with the addition of GFH009. Treatment will continue for as long as

    Jul 03, 2023
  • Phase I Data of GFH925 Monotherapy Treating CRC Released at ASCO

    Favorable safety/tolerability and promising antitumor activity of GFH925 monotherapy were observed among advanced colorectal cancer (CRC) patients harboring KRASG12C mutation according to preliminary results from a pooled analysis of two phase I studies(NCT05005234, NCT05497336).

    Jun 06, 2023
  • 1
  • 2
  • 3
  • 4
  • 5
Next
jinfangLOGOzuhejihekouhao-08.png
Company
Science
Media
Investors
Careers
Contact
GenFleet Therapeutics (Shanghai)

1206 Zhangjiang Road, Building A, Shanghai

021-6882 1388

201203

GenFleet Therapeutics (Zhejiang)

1 Yunhai Road, Building 3 (Southern Division), Level 4, Shaoxing City, Zhejiang Province

0575-8258 6890

312000

Offical Wechat
qrcode_for_gh_ae7817a32e15_258.jpg
GenFleeter Wechat
jinfangren-121.jpg
Copyright © 2021 GenFleet Therapeutics (Shanghai) Inc  |  沪ICP备18009875号